• A verdict in the New York civil business fraud trial of former President Donald Trump is now expected to arrive by early to mid-February, a court spokesman said.
• Manhattan Supreme Court Judge Arthur Engoron previously said he would try to issue his final ruling by the end of January.
• New York Attorney General Letitia James in a lawsuit accuses Trump, his two adult sons, his company and its top executives of fraudulently inflating Trump's net worth.

A verdict in the New York civil business fraud trial of former President Donald Trump — which had been anticipated Wednesday — is now expected to arrive in early to mid-February, a court spokesman said.

That new timeline for the written decision by Judge Arthur Engoron is still a "rough estimate" and "subject to modifications," said Alfred Baker, spokesman for the New York State Office of Court Administration.

"But that's the working plan now," Baker said.

Update: Appeals court denies Trump immunity in DC election case

Engoron at the end of Trump's trial last month in Manhattan Supreme Court said he would try to issue his final ruling by Wednesday, but noted there was "no guarantee" he would stick to that timeframe.

That day passed, with reporters habitually refreshing the court's docket website, without the final judgment being posted.

In the case, New York Attorney General Letitia James accuses Trump, the Trump Organization, his two adult sons and top company executives of inflating Trump's net worth on his financial statements in violation of a state antifraud law.

Engoron before the trial found the defendants liable for fraud.

The trial was conducted to determine penalties and resolve other claims of wrongdoing from James' lawsuit. Engoron conducted the trial without a jury.

Reuters first reported the new timeframe for the verdict.

Don't miss these stories from CNBC PRO:

• Forget the 'Magnificent 7,' these Nasdaq stocks are next in line to lead the rally, according to the charts
• Nvidia is now 'deeply overbought' and due for 'consolidation,' says chart analyst
• Eli Lilly's Zepbound is off to a strong start, but here's what needs to happen to push shares higher
• Investors are shifting into this type of bond fund at the fastest pace in three years